VAXXINITY INC-A (VAXX)
US92244V1044 - Common Stock
VAXX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. VAXX may be in some trouble as it scores bad on both profitability and health. VAXX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
VAXX had negative earnings in the past year.
In the past year VAXX has reported a negative cash flow from operations.
VAXX had negative earnings in each of the past 5 years.
VAXX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -128.51%, VAXX is not doing good in the industry: 83.56% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -424.66%, VAXX is doing worse than 78.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -128.51% | ||
| ROE | -424.66% | ||
| ROIC | N/A |
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VAXX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for VAXX has been increased compared to 1 year ago.
Compared to 1 year ago, VAXX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -15.06, we must say that VAXX is in the distress zone and has some risk of bankruptcy.
VAXX's Altman-Z score of -15.06 is on the low side compared to the rest of the industry. VAXX is outperformed by 82.02% of its industry peers.
VAXX has a Debt/Equity ratio of 0.99. This is a neutral value indicating VAXX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.99, VAXX is not doing good in the industry: 77.57% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
VAXX has a Current Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VAXX (1.89) is worse than 78.08% of its industry peers.
VAXX has a Quick Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
VAXX's Quick ratio of 1.89 is on the low side compared to the rest of the industry. VAXX is outperformed by 76.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.07% over the past year.
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q44.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
VAXX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.26% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VAXX. In the last year negative earnings were reported.
Also next year VAXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y3.5%
5. Dividend
5.1 Amount
No dividends for VAXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VAXXINITY INC-A
NASDAQ:VAXX (4/26/2024, 7:22:10 PM)
After market: 0.115 0 (-1.37%)0.1166
0 (-3.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -128.51% | ||
| ROE | -424.66% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y17.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y